APRE
Income statement / Annual
Last year (2024), Aprea Therapeutics, Inc.'s total revenue was $1.50 M,
an increase of 157.63% from the previous year.
In 2024, Aprea Therapeutics, Inc.'s net income was -$12.96 M.
See Aprea Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$1.50 M |
$583.23 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$9.36 M
|
$7.05 K
|
$16.40 M
|
$271.68 K
|
$229.61 K
|
$170.25 K
|
$8.32 K
|
$7.93 K
|
| Gross Profit |
-$7.86 M
|
$576.18 K
|
-$16.40 M
|
-$271.68 K
|
-$229.61 K
|
-$170.25 K
|
-$8.32 K
|
-$7.93 K
|
| Gross Profit Ratio |
-5.23
|
0.99
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$9.36 M
|
$7.63 M
|
$92.42 M
|
$23.90 M
|
$37.88 M
|
$20.95 M
|
$14.19 M
|
$13.39 M
|
| General & Administrative Expenses |
$6.46 M
|
$8.43 M
|
$20.97 M
|
$13.55 M
|
$14.93 M
|
$0.00
|
$2.29 M
|
$2.46 M
|
| Selling & Marketing Expenses |
$0.00
|
-$7.05 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.46 M
|
$8.42 M
|
$20.97 M
|
$13.55 M
|
$14.93 M
|
$8.42 M
|
$2.29 M
|
$2.46 M
|
| Other Expenses |
-$9.36 M
|
$0.00
|
-$16.40 M
|
-$271.68 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$6.46 M
|
$16.05 M
|
$96.99 M
|
$37.17 M
|
$52.81 M
|
$29.37 M
|
$16.49 M
|
$15.85 M
|
| Cost And Expenses |
$15.82 M
|
$16.06 M
|
$113.39 M
|
$37.45 M
|
$52.81 M
|
$29.54 M
|
$16.49 M
|
$15.85 M
|
| Interest Income |
$1.29 M
|
$1.22 M
|
$448.67 K
|
$1.65 K
|
$222.65 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$448.67 K
|
$0.00
|
$222.65 K
|
$156.35 K
|
$182.00
|
$15.00
|
| Depreciation & Amortization |
$22.32 K
|
$7.05 K
|
$4.40 K
|
$271.68 K
|
$229.61 K
|
$170.25 K
|
$8.32 K
|
$7.93 K
|
| EBITDA |
-$14.30 M |
-$14.28 M |
-$37.37 M |
-$36.86 M |
-$53.25 M |
-$27.89 M |
-$15.52 M |
-$15.18 M |
| EBITDA Ratio |
-9.52
|
-24.48
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-9.53
|
-26.53
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.36 M
|
$1.19 M
|
$730.20 K
|
$319.05 K
|
-$667.60 K
|
$1.48 M
|
$961.13 K
|
$662.13 K
|
| Income Before Tax |
-$12.96 M
|
-$14.29 M
|
-$112.66 M
|
-$37.13 M
|
-$53.48 M
|
-$28.06 M
|
-$15.53 M
|
-$15.19 M
|
| Income Before Tax Ratio |
-8.62
|
-24.5
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$12.96 M
|
-$14.29 M
|
-$112.66 M
|
-$36.54 M
|
-$53.92 M
|
-$28.06 M
|
-$15.53 M
|
-$15.19 M
|
| Net Income Ratio |
-8.62
|
-24.5
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.35 |
-3.95 |
-1359.79 |
-34.88 |
-50.61 |
-26.28 |
-22.06 |
-21.58 |
| EPS Diluted |
-2.35 |
-3.95 |
-1359.79 |
-34.88 |
-50.61 |
-26.28 |
-22.06 |
-21.58 |
| Weighted Average Shares Out |
$5.51 M
|
$3.62 M
|
$82.85 K
|
$1.06 M
|
$1.06 M
|
$1.00 M
|
$703.78 K
|
$703.78 K
|
| Weighted Average Shares Out Diluted |
$5.51 M
|
$3.62 M
|
$82.85 K
|
$1.06 M
|
$1.06 M
|
$1.00 M
|
$703.78 K
|
$703.78 K
|
| Link |
|
|
|
|
|
|
|
|
